NEWS HIGHLIGHTS
Published Studies Related to Arestin (Minocycline)
Glatiramer Acetate in Combination with Minocycline in Patients with Relapsing-Remitting Multiple Sclerosis: Results of a Canadian, Multicenter, Double-Blind, Placebo-Controlled Trial. [2009.09.23]
Minocycline is proposed as an add-on therapy to improve the efficacy of glatiramer acetate in relapsing-remitting multiple sclerosis. The effect of minocycline plus glatiramer acetate was evaluated in this double-blind, placebo-controlled study by determining the total number of T1 gadolinium-enhanced lesions at months 8 and 9 in patients who were starting glatiramer acetate and had at least one T1 gadolinium-enhanced lesion on screening magnetic resonance imaging...
Local minocycline as an adjunct to surgical therapy in moderate to severe, chronic periodontitis. [2008.06]
CONCLUSION: Applications of local minocycline as an adjunct to surgery in adults with moderate to severe, chronic periodontitis were associated with statistically significant greater reductions in probing depth than surgery alone.
A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. [2008.05]
OBJECTIVE: To report an 18-month follow-up on creatine and minocycline futility study, the Neuroprotective Exploratory Trials in Parkinson Disease, Futility Study 1 (NET-PD FS-1). BACKGROUND: The NET-PD FS-1 futility study on creatine and minocycline found neither agent futile in slowing down the progression of disability in Parkinson disease (PD) at 12 months using the prespecified futility threshold. An additional 6 months of follow-up aimed to assess safety and potential interactions of the study interventions with antiparkinsonian therapy... CONCLUSIONS: Data from this small, 18-month phase II trial of creatine and minocycline do not demonstrate safety concerns that would preclude a large, phase III efficacy trial, although the decreased tolerability of minocycline is a concern.
Topical minocycline for managing symptoms of recurrent aphthous stomatitis. [2008.01]
Recurrent aphthous stomatitis (RAS) is a common ulcerative condition of the oral mucosa. In this study, minocycline oral rinses were compared to a placebo in patients suffering from frequent episodes of RAS.The findings of this study show that minocycline oral rinses reduce pain in patients with RAS and may have implications for the use of minocycline in other non-infectious inflammatory ulcerative oral mucosal diseases.
Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. [2007.12.01]
PURPOSE: To evaluate the ability of either oral minocycline, topical tazarotene or both, to reduce or prevent cetuximab-related acneiform rash when administered starting on day 1 of cetuximab therapy... CONCLUSION: Prophylaxis with oral minocycline may be useful in decreasing the severity of the acneiform rash during the first month of cetuximab treatment. Topical tazarotene is not recommended for management of cetuximab-related rash.
Clinical Trials Related to Arestin (Minocycline)
Pilot Study of Minocycline in Huntington's Disease [Active, not recruiting]
This study is being conducted to assess the impact of minocycline on the progression of
symptoms of HD. The study will also assess whether it is reasonable to continue with further
study of minocycline in HD. We will measure the effect of minocycline on HD by measuring the
change in Huntington's disease symptoms.
Comparison of Tazarotene and Minocycline Therapies for Maintenance of Facial Acne Vulgaris [Completed]
Minocycline for HIV+ Cognitive Impairment in Uganda [Recruiting]
Purpose: The purpose of the study is to assess the safety and effectiveness of minocycline,
an antibiotic, in the treatment of HIV-associated cognitive impairment in Uganda.
Study Design: Treatment, 24-week Randomized, Placebo-Controlled, Double-Blind Phase with
Optional 24-week Open Label Phase for Subjects with a CD4 Count in the 251-350 Range
- Arm 1: Minocycline 100 mg orally every 12 hours (50 subjects)
- Arm 2: Matching placebo orally every 12 hours (50 subjects)
Primary Outcome Measure:
ยท To examine whether minocycline treatment will improve cognitive performance after 24 weeks
compared to baseline
Secondary Outcome Measures:
- To examine whether minocycline treatment for 24 weeks is safe and well-tolerated in
individuals with HIV-associated cognitive impairment
- To examine whether minocycline treatment for 48 weeks is safe and well-tolerated in
individuals with HIV-associated cognitive impairment
- To examine whether minocycline treatment for 24 weeks improves functional impairment
Intrapleural Minocycline After Simple Aspiration for the Prevention of Primary Spontaneous Pneumothorax [Recruiting]
The estimated recurrence rate of primary spontaneous pneumothorax is 23-50% after the first
episode, and the optimal treatment remains unknown. In the recently published British
Thoracic Society (BTS) guidelines, simple aspiration is recommended as first line treatment
for all primary pneumothoraces requiring intervention. However, the 1 year recurrence rate
of this procedure was as high as 25-30%, making it inappropriate as a standard of care.
Intrapleural instillation of a chemical irritant (chemical pleurodesis) is an effective way
to shorten the duration of air leaks and reduce the rates of recurrent spontaneous
pneumothorax in surgical and non-surgical patients. Many chemical irritants (tetracycline,
talc, and minocycline) have been used to decrease the rate of recurrence in spontaneous
pneumothorax. Tetracycline, which was the most commonly used irritant, is no longer
available. Talc insufflation of the pleural cavity is safe and effective for primary
spontaneous pneumothorax. However, it should be applied either with surgical or medical
thoracoscopy. Minocycline, a derivative of tetracycline, is as effective as tetracycline in
inducing pleural fibrosis in rabbits. In the previous studies, we have shown that additional
minocycline pleurodesis is a safe and convenient procedure to decrease the rates of
ipsilateral recurrence after thoracoscopic treatment of primary spontaneous pneumothorax. In
the present study, additional minocycline pleurodesis will be randomly administered in
patients with first episode of primary spontaneous pneumothorax after simple aspiration to
test if it can reduce the rate of recurrence.
Long-Term Safety of Minocycline in Patients With Gum Disease [Recruiting]
This study will look at the safety of using the study medicine for a long time. It will see
if the germs get used to the medicine, making it not work as well, if it's used by people
with gum disease for a long time.
|
